Currently, no therapies exist for treating and improving outcomes in patients with severe peripheral artery disease (PAD). MicroRNA93 (miR93) has been shown to favorably modulate angiogenesis and to reduce tissue loss in genetic PAD models. However, the cell-specific function, downstream mechanisms, or signaling involved in miR93-mediated ischemic muscle neovascularization is not clear. Macrophages were best known to modulate arteriogenic response in PAD, and the extent of arteriogenic response induced by macrophages is dependent on greater M2 to M1 activation/polarization state. In the present study, we identified a novel mechanism by which miR93 regulates macrophage polarization to promote angiogenesis and arteriogenesis to revascularize ischemic muscle in experimental PAD.
P eripheral arterial disease (PAD) is a major atherosclerotic complication in which occlusions in arteries to organs other than the heart and brain cause tissue ischemia, and legs are most frequently affected. 1 Severe PAD often results in pain at rest and nonhealing ulcers that can lead to amputation. 1 As a result of the atherosclerotic occlusions, blood flow to the distal tissue becomes dependent on the degree of vascular remodeling (arteriogenic and angiogenic) in the ischemic muscle. MicroRNAs (miRs) are short noncoding RNA sequences (≈18-22 nucleotide length) that are classically thought to regulate expression of a single or several functionally related target mRNAs by specific base pairing with the binding sites in their 3′ untranslated region (UTR). [2] [3] [4] miR93 is one of the microRNAs in the miR106b-93- 25 cluster that has been demonstrated to promote tumor angiogenesis. 5 We have previously shown that miR93 improved the extent of angiogenesis in the distal ischemic muscle and perfusion in experimental PAD. 6 Furthermore, the miR106b-93-25 cluster has been shown to play an important role in regulating bone marrow-derived stromal cell recruitment into ischemic muscle to promote perfusion. 7 However, the downstream mechanisms and the signaling involved in miR93-mediated perfusion recovery are not completely understood.
A number of different resident and mobilized cells are active participants in forming new blood vessels. In experimental PAD, monocyte/macrophage recruitment into the occluded vessel can induce a potent arteriogenic response [8] [9] [10] ; however, limited information is available on the role of the macrophage activation state in regulating this process. Classically activated macrophages (M1 polarized) in response to lipopolysaccharide and/or interferon-γ are proinflammatory and cytotoxic 11 and alternatively activated macrophages (M2 polarized), seen in response to interleukin (IL)-4 and IL-13, are anti-inflammatory and reparative. 11 Although intermediate states clearly exist between M1 and M2, these macrophage subtypes 12 are considered to be dominant modulators in several cardiovascular pathologies. 13 The role of macrophage polarization in modulating an angiogenic response in distal ischemic muscle to regulate neovascularization is not clear. Although a few genes, including Syndecan-4, 14 IL-19, 15 protease-activated receptor-2, 16 and prolyl hydroxylase domain protein-2, 10, 17 were shown to regulate macrophage polarization in experimental PAD, data on whether microRNAs can regulate macrophage polarization in ischemic skeletal muscle are extremely limited. Knowing that miR93 can inhibit inflammatory cytokine production in lipopolysaccharide-stimulated macrophages, 18 we sought to determine the role of miR93 in macrophage polarization, arteriogenesis, and angiogenesis and to establish the potential genes regulated by miR93 in macrophages. Macrophages that infiltrate the ischemic muscle are polarized to the M1 phenotype because of the existing cytokine milieu in ischemic tissue, and increased M1 macrophages or sustained M1 phenotype can significantly lessen the arteriogenic response to decrease the perfusion recovery. 19, 20 Furthermore, because of the reversible nature of macrophage polarization (M2 phenotype to M1 phenotype and vice versa), 21 it has been a challenge to pharmacologically sustain M2 macrophage polarization to promote vascular remodeling and perfusion recovery in ischemic muscle. Thus, there is significant interest in identifying therapies that can promote and sustain the M2 phenotype in ischemic cardiovascular diseases, including PAD.
METHODS
Expanded Methods can be found in the online-only Data Supplement.
Mice
Homozygous miR106b-93-25 −/− (on C57Bl/6 background) and C57Bl6 (wild-type [WT]) mice were bred in the University of
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What Is New?
• Within the miR106b-93-25 cluster knockout, miR93 overexpression alone is sufficient to enhance angiogenesis, arteriogenesis, and perfusion in ischemic muscle via increased M2-like macrophages.
• miR93 targets interferon regulatory factor-9 to inhibit immune response gene-1 and itaconic acid generation in macrophages to induce M2-like macrophage polarization.
• miR93 overexpression modulates a paracrine effect on macrophages to induce angiogenesis and skeletal muscle recovery under hypoxic conditions in vitro.
• We also provide the first evidence that induction of the interferon regulatory factor-9-immune response gene-1-itaconic acid pathway in endothelial cells can inhibit angiogenesis in vitro.
What Are the Clinical Implications?
• No current medical therapies exist that are capable of promoting both arteriogenesis and angiogenesis in patients with peripheral artery disease.
• miR93 increased endothelial angiogenic potential and in macrophages increased the M2-like phenotype, which contributed to skeletal muscle recovery and perfusion in preclinical peripheral artery disease.
• Our data demonstrate that miR93 induces beneficial effects in multiple cells that can enhance perfusion in ischemic limb and identify miR93 as a putative therapeutic target for clinical peripheral artery disease.
Virginia vivarium. Animal studies were approved by the University of Virginia Institutional Animal Care and Use Committee.
Animal Model of Hind-Limb Ischemia and Perfusion Recovery
Unilateral femoral artery ligation and excision was performed on age-and sex-matched 12-to 16-week-old animals.
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Human Samples
The Institutional Review boards at Duke University, University of Colorado, and University of Virginia approved the research protocols with human samples.
Cell Transfections
MicroRNA transfections were performed by SiPORT NeoFX reagent, and plasmid transfections were performed by Lipofectamine-3000 according to the manufacturers' instructions.
Statistics
GraphPad Prism-6 was used to determine the statistical significance of the data. Equality of variance was checked by the Brown-Forsythe test, and the Welch correction was applied to the t test analysis of the data that did not pass the equal variance test. The statistical test for each individual experiment is provided in the figure legends. Figure 1A) . In this HLI model, shear stress in the occluded inflow vessels (in adductor muscle) induces arteriogenesis, and ischemia in the distal leg (gastrocnemius muscle) induces angiogenesis. [25] [26] [27] [28] Hence, we examined arteriogenic induction in the adductor muscle by α-smooth muscle actin (α-SMA) immunostaining and both arteriogenic and angiogenic induction in gastrocnemius muscle by α-SMA and CD31 immunostaining. α-SMA immunostaining in the ischemic adductor muscle (IAM) from miR106b-93-25 −/− versus WT showed significantly lower (≈2 times) arteriolar density (percent average of α-SMA + vascular structures >50 µm per image; P=0.002; Figure 1B) . Furthermore, immunostaining of α-SMA and CD31 (percent average of CD31 + cells per muscle fiber area 29 ) in ischemic gastrocnemius muscle (IGA) from miR106b-93-25 −/− versus WT showed a significant decrease in arteriogenesis (≈3 times; P=0.0001; Figure 1C ) and angiogenesis (P>0.03; Figure 1D ).
RESULTS
We examined whether decreased vascular density in miR106b-93-25 −/− ischemic muscle correlates with differences in macrophage numbers or with their polarization state by flow cytometry (gating strategy presented in Figure II in the online-only Data Supplement). In nonischemic muscle, there was no significant difference in the total macrophage numbers (CD11b In ischemic muscle, no significant difference in total macrophage numbers (IGA in Figure 2A and IAM in Figure 2D ) between miR106b-93-25 −/− and WT was observed. However, an increase in M1-like macrophages (IGA, ≈2 times) and a significant decrease in M2-like macrophages (IGA, ≈3 times, P=0.009; IAM, ≈2 times, P=0.01) in miR106b-93-25 −/− versus WT was observed (Figure 2A-2F) . Analysis of tissue-infiltrating macrophages showed no significant differences in total macrophage numbers (IGA in Figure 2G and IAM in Figure 2J ) between miR106b-93-25 −/− and WT. However, a significant decrease in M2-like tissue-infiltrating macrophages (IGA, ≈3 times, P=0.008; IAM, ≈5 times, P=0.003) in miR106b-93-25 −/− versus WT was observed ( Figure 2G -2L). Analysis of tissue-resident macrophages showed no significant differences in total or M1-like macrophages but a significant decrease in M2-like macrophages (IGA, ≈2 times, P<0.023; IAM, ≈4 times, P=0.005) in miR106b-93-25 −/− versus WT ( Figure 2M-2R ). Representative flowcharts for Figure 2 are presented in Figure IV in the online-only Data Supplement.
We next examined whether miR93 contributes to differences in bone marrow niche by predisposing bone marrow monocytes to proinflammatory M1-like phenotype. Although no significant differences in the total monocytes (CD11b We next determined which microRNA deficiency in miR106b-93-25 −/− plays a role in modulating angiogenesis and macrophage polarization. In vitro angiogenesis experiments revealed that miR93 mimic significantly induced endothelial branching on growth factor-reduced Matrigel (P<0.05; Figure VI in the online-only Data Supplement) versus scrambled mimic. Although miR106b mimic significantly decreased endothelial branching, miR25 mimic showed no significant difference in endothelial branching on growth factor-reduced Matrigel versus scrambled mimic (P<0.05; Figure VI in the onlineonly Data Supplement), suggesting that lack of miR93 in the miR106b-93-25 cluster might be responsible for decreased angiogenesis and arteriogenesis in the miR106b-93-25 −/− IGA versus WT. We next transfected macrophages (Raw264.7, a macrophage cell line) with miR106b, miR93, or miR25 mimics or scrambled mimics (control, same concentration as mimics; Figure VIIA -VIIC in the online-only Data Supplement) under normal and hypoxia serum starvation (HSS) conditions and examined for their polarization state by quantitative polymerase chain reaction (qPCR) analysis of inducible nitric oxide synthase (iNOS; M1 polarization marker) and arginase 1 (Arg1; M2 polarization marker). qPCR analysis showed that macrophages treated with miR93 mimic significantly increased Arg1 expression (≈6 times; P=0.01; Figure 3A ) versus scrambled mimic. miR106b mimic or miR25 mimic did not induce any significant differences in Arg1 or iNOS expression versus scrambled mimic in macrophages under normal conditions ( Figure VIIIA and VIIIB in the online-only Data Supplement).
We next determined whether miR93 (or miR106b and miR25) has the capacity to sustain M2-like polarization under M1-like polarizing conditions relevant for tissue ischemia found in PAD. Hence, we examined the status of macrophage polarization under HSS. qPCR analysis showed that HSS significantly induced M1-like polarization, evident by a significant increase in iNOS expression and significant decrease in Arg1 expression ( Figure  IX in the online-only Data Supplement). qPCR analysis showed that miR93 transfection significantly induced Arg1 expression (P=0.01; Figure 3B ) with no changes in iNOS expression in HSS macrophages versus scrambled mimic. Increased M2-like phenotype in macrophages under normal and HSS conditions transfected with miR93 mimic inversely correlated with significantly decreased reactive oxygen species levels (measured by CellROX green, which emits photostable fluorescence on oxidation by reactive oxygen species) under normal (P=0.03; Figure Figure 3C , left) with a concomitant increase in iNOS expression (P=0.008; Figure 3C , right) versus scrambled antagomir under normal conditions. Antagomir93 significantly decreased Arg1 expression (P=0.001; Figure 3D ) with no changes in iNOS expression versus scrambled antagomir in HSS macrophages.
To determine whether M2-like polarization induced by miR93 in macrophages can enhance the angiogenic capacity of endothelial cells, we next treated endothelial cells with conditioned media (CM) from macrophages transfected with miR93 mimic, antagomir93, or respective scrambled controls in vitro. Endothelial cells treated with CM from miR93 mimic demonstrated significantly more capillary-like tube formation (P<0.05; Figure 3E ) and CM from antagomir93 treatment showed significantly less (P=0.002; Figure 3F ) capillary-like tube formation versus respective controls. These data strongly suggested that increased miR93 expression induces M2-like polarization in macrophages to promote angiogenesis.
We next transfected freshly isolated human peripheral blood monocytes (HPBMNCs) with miR93 mimic or scrambled mimics under normal or HSS conditions. Flow cytometry showed that miR93 mimic significantly increased the numbers of CD206 + HPBMNCs versus scrambled mimic under normal (≈2 times; P=0.008; Figure 3G ) and HSS (P<0.05; Figure 3H ) conditions. qPCR analysis of HPBMNCs transfected with miR93 also showed a significant increase in CD206 expression versus scrambled mimic under normal (P<0.05; Figure 3I ) and HSS (P=0.002; Figure 3J ) conditions. Furthermore, qPCR analysis of human peripheral BMDMs transfected with miR93 also showed a significant increase in CD206 expression versus scrambled mimic under normal (P=0.04; Figure 3K Figure 5A ). Immunostaining for α-SMA and CD31 in the IGA of miR106b-93-25 −/− HLI+miR93-plasmid showed a significant increase in arteriolar density (α-SMA; ≈2 times; P=0.004; Figure 5B ) and microvascular density (CD31; P<0.03; Figure 5C ). Furthermore, although a significant increase in cell death (total and endothelial) in online-only Data Supplement) associated with muscle function. From these data, we hypothesized that increased M1-like macrophages in miR106b-93-25 −/− ischemic muscle paracrinally aggravated skeletal muscle injury. To confirm our hypothesis, we examined the role of miR93 in modulating the paracrine effects of macrophages in regulating skeletal muscle (C2C12) cell survival in vitro. Terminal deoxynucleotidyl transferase dUTP nick-end labeling analysis showed that (1) CM from antagomir93-transfected macrophages (M1-like phenotype) induced significantly higher muscle cell death versus scrambled antagomir (P=0.01; Figure XVIIA Figure XVIIC in the online-only Data Supplement). These data suggested that miR93 deficiency results in M1-like polarization that contributes to aggravated skeletal muscle injury through paracrine effects. Cytokine/chemokine analysis of the CM from HSS macrophages transfected with miR93 mimic versus scrambled mimic showed significantly lower levels of cytokines that are consistent with the M1 phenotype, including tumor necrosis factor-α, IL-1β, IL-6, and interferon-γ, in addition to IL-1α, IL-7, eotaxin, and CXCL1 (P<0.05, Figure XVIII in the online-only Data Supplement). Furthermore, a significant increase in macrophage inflammatory protein-2, monocyte chemoattractant protein-1, interferon-γ-induced protein 10, and granulocyte-colony stimulating factor levels were observed in CM from HSS macrophages transfected with miR93 mimic versus scrambled mimic (P<0.05; Figure XVIII in the online-only Data Supplement). These data confirmed that miR93 inhibits M1 cytokine production by macrophages subject to HSS to increase skeletal muscle cell survival. We also examined the role of miR93 in regulating paracrine effects of skeletal muscle on macrophage polarization in vitro. qPCR analysis showed that macrophages treated with CM collected from muscle cells (C2C12) transfected with miR93 mimic demonstrated increased Arg1 expression (P=0.007) without differences in iNOS expression compared with CM from muscle cells transfected with scrambled mimic, indicating that miR93 results in paracrine effects to increase an M2-like phenotype in macrophages ( Figure XVIID in the online-only Data Supplement) under normal conditions. We next systematically examined the role of top upregulated genes in modulating macrophage function −/− mice. n=6. *P<0.05 considered significant. Unpaired t test. F, qPCR analysis of miR93 expression normalized to Sno202 (housekeeping microRNA) in macrophages under normal and HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. G, qPCR analysis of IRG1 expression normalized to Hprt in macrophages under normal and HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. H, Ratio of arginase 1 (Arg1):inducible nitric oxide synthase (iNOS) expression in macrophages transfected with control (con; scrambled) or IRG1-expressing plasmid (IRG-1 Exp-Plmd) under normal growth conditions. n=6. *P<0.05 considered significant. Unpaired t test. I, Ratio of Arg1:iNOS in macrophages transfected with control (Con; scrambled) plasmid and IRG1 Exp-Plmd under HSS. n=6. *P<0.05 considered significant. Unpaired t test. J, Ratio of Arg1:iNOS expression in macrophages transfected with Scrbd-Antg+scrambled plasmid (Con Plmd) or Antg93+IRG1 Crispr-cas9 knockout plasmid (IRG1 KO plmd) under normal growth conditions. n=6. *P<0.05 considered significant. Unpaired t test. K, Ratio of Arg1:iNOS expression in macrophages transfected with Scrbd-Antg+scrambled plasmid (Con Plmd) or Antg93+IRG1 KO plmd under normal growth conditions. n=6. *P<0.05 considered significant. Unpaired t test. L, qPCR analysis of IRF9 expression in macrophages transfected with scrambled mimic (Scrbd Mim) or miR93 mimic (miR93 Mim) under normal and HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. M, qPCR analysis of IRF9 expression in macrophages transfected with Scrbd Antg or Antg93 under normal and HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. N, Luciferase activity in macrophages transfected with IRF9 3′ untranslated region luciferase plasmid followed by transfection with Scrbd Mim or miR93 Mim under normal or HSS conditions. n=4. *P<0.05 considered significant. Unpaired (Continued ) and assessed whether the genes are miR93 targets in vitro. qPCR analysis of CXCL2 showed significantly higher CXCL2 expression in miR106b-93-25 −/− ischemic muscle (≈18 times; P<0.05, experimentally confirming RNA sequencing data) versus WT, and miR106b-93-25 −/− ischemic muscle treated with miR93-expressing plasmid decreased CXCL2 expression comparable to WT ( Figure XIXA and XIXB in the online-only Data Supplement). In vitro, CXCL2 treatment significantly decreased Arg1 expression in macrophages under normal and HSS conditions versus respective untreated controls, indicating that CXCL2 induces M1-like polarization ( Figure XIXC -XIXF in the online-only Data Supplement). However, antagomir93 treatment did not show any significant differences in CXCL2 expression under normal or HSS conditions versus respective controls, indicating that CXCL2 is not regulated by miR93 in macrophages ( Figure XIXG and XIXH in the online-only Data Supplement).
We next examined whether IRG1 is modulated by miR93 in experimental PAD. qPCR analysis of IRG1 showed no significant differences in IRG1 levels between WT and miR106b-93-25 −/− nonischemic muscle (Figure 7A) . However, miR106b-93-25 −/− ischemic muscle had significantly higher IRG1 expression (3 days after HLI: ≈85 times; P<0.05, confirming RNA sequencing data) versus WT ( Figure 7B) , and miR106b-93-25 −/− ischemic muscle treated with miR93-expressing plasmid had decreased IRG1 expression comparable to WT ( Figure 7B ). We next examined whether miR93 regulates IRG1 expression in macrophages. Antagomir93 did not change IRG1 expression in macrophages under normal conditions versus control ( Figure 7C ), but under HSS conditions, antagomir93 induced a significant increase in IRG1 expression (P=0.006) versus control ( Figure 7D ). In addition, a significant increase in IRG1 expression was observed in HSS miR106b-93-25 −/− -BMDM versus HSS WT-BMDM (≈2 times; P<0.03; Figure 7E ). qPCR analysis of endothelial cells transfected with miR93 mimic showed a significant decrease in IRG1 expression under normal (P=0.02; Figure Furthermore, qPCR analysis showed a significant decrease in miR93 levels in macrophages under HSS versus control conditions (P<0.0001; Figure 7F ) with a concomitant increase in IRG1 levels in HSS macrophages versus control conditions (P<0.0001; Figure 7G ). Decreased miR93 levels and increased IRG1 levels in macrophages under HSS versus control conditions correlated with increased M1-like phenotype in macrophages. We next examined the function of IRG1 in modulating macrophage polarization. In vitro, IRG1 overexpression ( Figure XXIA in the online-only Data Supplement) in macrophages significantly decreased the Arg1:iNOS ratio under normal (P=0.001; Figure 7H ) and HSS (P=0.01; Figure 7I ) conditions.
We next wanted to determine whether miR93 targeting IRG1 regulates macrophage polarization. Because miR93 inhibition induced IRG1 expression and correlated with increased iNOS expression, we predicted that IRG1 inhibition in antagomir93-transfected macrophages will result in decreased iNOS expression and/or increased Arg1 expression, confirming that IRG1 regulates miR93-mediated macrophage polarization. Hence, we transfected macrophages with IRG1-Crispr/Cas9 knockout plasmid followed by antagomir93 transfection (Figure XXIB in the online-only Data Supplement). Macrophages treated with equal concentrations of scrambled plasmid and scrambled antagomir served as controls. qPCR analysis of Arg1 and iNOS expression in macrophages transfected with IRG1-Crispr/Cas9 knockout plasmid and antagomir93 under normal and HSS conditions showed a significant increase in Arg1:iNOS expression under normal conditions (P=0.0004; Figure 7J ) but no significant difference in Arg1:iNOS expression under HSS conditions ( Figure 7K ). These data showed that miR93 regulates IRG1 expression to modulate macrophage polarization in experimental PAD.
miR93 Targets Interferon Regulatory Factor-9 to Regulate IRG1 Expression and Macrophage Polarization
To examine whether IRG1 is a direct miR93 target, macrophages were transfected with IRG1 3′ UTR luciferase plasmid and later with miR93 mimic or scrambled mimics and tested for differences in IRG1 3′UTR luciferase activity. No significant differences in luciferase activity in macrophages expressing IRG1 3′ UTR between miR93 mimic and scrambled mimic under either normal or HSS conditions ( Figure XXII in the online-only Data Supplement) were observed. Because IRG1 did not ap- Figure 7 Continued. t test. O, qPCR analysis of IRG1 expression in macrophages transfected with IRF9-expressing plasmid (IRF9 Plmd) or Con Plmd under normal or HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. P, qPCR analysis of Arg1 and iNOS expression in macrophages transfected with IRF9 Plmd or Con Plmd under normal conditions. n=6. *P<0.05 considered significant. Unpaired t test. Q, qPCR analysis of Arg1 and iNOS expression in macrophages transfected with IRF9 Plmd or Con Plmd under HSS conditions. n=6. *P<0.05 considered significant. Unpaired t test. Data presented as mean±SEM.
pear to be a direct miR93 target, we predicted that miR93 targets another gene that has the ability to modulate IRG1 expression. A recent report has shown that interferon regulatory factor (IRF)-1 can transcriptionally regulate IRG1 expression, 34 and the miRanda algorithm predicted that IRF1 and IRF9 are miR93 targets. qPCR analysis showed miR93 mimic did not decrease IRF1 expression ( Figure XXIIIA and XXIIIB in the online-only Data Supplement); antagomir93 did not increase IRF1 expression ( Figure XXIIIC and XXIIID in the online-only Data Supplement) in normal or HSS macrophages versus controls.
We next examined whether IRF9 is an miR93 target in macrophages. qPCR analysis showed that miR93 mimic significantly decreased IRF9 expression in normal (P<0.05; Figure 7M , left) and HSS (P=0.02; FigFigure 8 . Decreased miR93 levels correlate with activation of interferon regulatory factor-9 (IRF9)-immunoresponsive gene-1 (IRG1)-itaconic acid pathway in human peripheral artery disease (PAD) and human monocyte/ macrophages.
A, Quantitative polymerase chain reaction (qPCR) analysis of miR93 expression in normal and PAD muscle biopsies: normal (NL), n=8; PAD, n=8. *P<0.05 considered significant. Unpaired t test. B, qPCR analysis of IRF9 expression in normal and PAD muscle biopsies: NL, n=8; PAD, n=8. *P<0.05 considered significant. Unpaired t test. C, qPCR analysis of IRG1 expression in normal and PAD muscle-biopsies: NL, n=8; PAD, n=8. *P<0.05 considered significant. Unpaired t test. D, qPCR analysis of IRF9 expression in human peripheral blood monocytes (HPBMNCs) transfected with scrambled mimic (Scrbd Mim) or miR93 mimic (miR93 Mim) under normal and hypoxia serum starvation (HSS) conditions. n=4. *P<0.05 considered significant. To examine whether IRF9 is a direct miR93 target, macrophages were transfected with IRF9 3′UTR luciferase expressing plasmid and later with miR93 mimic or scrambled mimic and tested for differences in luciferase activity. miR93 mimic significantly decreased luciferase activity in macrophages expressing IRF9 3′ UTR versus scrambled mimic under both normal (P=0.003; Figure 7N , left) and HSS (P<0.05; Figure 7N , right) conditions, indicating that IRF9 is an miR93target in macrophages. Furthermore, qPCR analysis showed that IRF9 overexpression ( Figure Considering future miR93 therapeutics, we sought to determine the potential for modulation of the miR93-IRF9-IRG1 axis in humans with PAD. We compared muscle biopsies from a subgroup of PAD and age-and sexmatched control subjects from a prior National Institutes of Health study. 35 qPCR analysis showed lower levels of miR93 in PAD muscle biopsies compared with controls (≈3 times; P=0.04; Figure 8A ). Lower levels of miR93 in PAD muscle biopsies were associated with higher levels of IRF9 (≈2 times; P=0.03; Figure 8B ) and IRG1 expression (≈12 times; P=0.04; Figure 8C ) compared with normal. This suggests that miR-93 overexpression could promote anti-inflammatory macrophages to induce angiogenesis and/or arteriogenesis in humans with PAD.
Subsequently, we transfected freshly isolated HPBMNCs as well as human peripheral BMDMs with miR93 mimic or scrambled mimic under normal or HSS conditions and examined differences in IRF9 and IRG1 expression. qPCR analysis showed that miR93 mimic significantly decreased normal and HSS HPBMNC IRF9 (normal, P=0.02; HSS, P=0.03; Figure 8D ) and IRG1 (normal, ≈5 times, P=0.01; HSS, ≈2 times, P=0.003; Figure 8E ) expression, and normal and HSS human peripheral blood monocyte-derived macrophage IRF9 (normal, P=0.03; HSS, ≈5 times, P=0.04; Figure 8F ) and IRG1 (normal, P=0.02; HSS, P=0.0002; Figure 8G ) expression versus scrambled mimic, confirming that the miR93-IRF9-IRG1 pathway is active in human monocyte/ macrophages.
miR93 Decreases IRG1 and Itaconic Acid Production in Macrophages to Induce M2-Like Polarization
On the basis of previously published data demonstrating that IRG1 regulates itaconic acid production in lipopolysaccharide-treated macrophages to modulate macrophage function, 36 we next examined whether increased itaconic acid production caused by increased IRG1 expression (on miR93 inhibition) in macrophages regulates macrophage polarization. Macrophages treated with 5 and 10 mmol/L (concentrations chosen on the basis of itaconic acid levels in lipopolysaccharide-treated macrophages 36 ) showed a significant decrease in Arg1 expression and a significant increase in iNOS expression (P<0.05; Figure 8H ) versus untreated controls under normal conditions. Under HSS conditions, although 5 mmol/L itaconic acid significantly decreased Arg1 expression, no significant difference in Arg1 expression was observed with 10 mmol/L itaconic acid treatment (P<0.05; Figure 8I , left). However, both 5 and 10 mmol/L itaconic acid treatments significantly induced iNOS expression (P<0.05; Figure 8I , right) versus untreated HSS controls. These data indicated that increased itaconic acid levels in macrophages can induce a proinflammatory phenotype. In vitro, itaconic acid significantly decreased endothelial branching in a dose-dependent manner versus untreated controls (P>0.05; Figure XXVC in the online-only Data Supplement). These data indicated that the induction of IRF9-IRG1-itaconic acid pathway also has the ability to decrease angiogenesis.
To obtain a direct correlation between miR93 and itaconic acid production, we next examined whether miR93 inhibition can induce itaconic acid levels by liquid chromatography-tandem mass spectroscopy analysis. Correlating with increased IRG1-levels by miR93 inhibition, antagomir93 transfection induced a significant increase in the levels of itaconic acid production in normal and HSS macrophages versus scrambled antagomir (normal, P=0.02; HSS, P=0.01; Figure 8J ).
DISCUSSION
The extent of skeletal muscle perfusion recovery after HLI depends on favorable synergistic function among multiple cell types 15, [19] [20] [21] and is related to the degree of both angiogenic and arteriogenic induction after experimental PAD. 26, 28, 37 The ability of macrophages to favorably modulate these processes is dependent on their polarized state, especially in diseased tissue. 9, 17, 19 M2-like macrophages play critical roles in inflammation resolution by secreting anti-inflammatory cytokines, including IL-10 and transforming growth factor-β, that help with tissue repair 38, 39 and by secreting growth factors 40, 41 that induces arteriogenesis and angiogenesis. On the basis of these functions, it is well accepted that increased M2-like macrophages are beneficial for the recovery of ischemic muscle. 19, 20 However, the first wave of macrophages that infiltrate the ischemic muscle are polarized to a proinflammatory phenotype because of the highly inflammatory and ischemic environment existing in the PAD muscle, thereby contributing to aggravation of tissue damage and inhibition of the recovery/adaptive processes. 19, 20 Therapies that are aimed at increasing the anti-inflammatory macrophage population in ischemic muscle are extremely limited and are often met with unsuccessful outcomes owing to the reversible nature of M2 to M1-like polarized states and vice versa. 13, 19, 20, 42 Hence, therapies that not only increase M2-like macrophages but also can sustain the M2-like phenotype even in M1-like polarizing conditions are much more likely to be successful as a therapeutic in PAD.
General studies aimed at understanding the molecular mechanism in macrophage polarization include lipopolysaccharide/interferon-γ treatments for M1-like polarization and IL-4/IL-10 for M2-like polarization. 12 However, we show that HSS, a plausible in vitro counterpart to in vivo ischemic challenge, 6 can itself induce a distinct proinflammatory-phenotype without any external cytokine effect, thus enabling us to study the role of miR93 in modulating macrophage activation in more pathology-relevant condition. An important finding of our study is the finding that macrophages, specifically M2-like macrophages, have the ability to induce angiogenesis in the IGA. Several previous studies have demonstrated that monocytes/macrophages recruited into the adductor muscle at the site of vascular occlusion induce collateralization/arteriogenesis. 10, [43] [44] [45] [46] However, the specific role of M2-like macrophages in inducing angiogenesis to improve the microvascular perfusion in the IGA is not clear. In our present study, we demonstrate the ability of M2-like macrophages to induce ischemic muscle angiogenesis and arteriogenesis by adoptive transfer of BMDM experiments that showed that the miR106b-93-25 −/− IGA that received WT-BMDM has significantly improved vascular density compared with WT ischemic muscle that received miR106b-93-25 −/− -BMDM. These data not only show a novel aspect of cell-specific miR93 function but also point toward the translational potential of miR93 in PAD.
In our present study, genetic deficiency of miR93 (along with mir106b and miR25) significantly decreased perfusion, 7 suggesting that miR93 also plays a role in regulating perfusion, consistent with our earlier publication. 6 Reintroduction of miR93 in miR106b-93-25-deficient mice improved perfusion to levels similar to those of WT (C57Bl/6; day 21 after HLI: C57BL6, 79.23±5.5% versus miR106b-93-25 −/− , 55.78±6% versus miR106b-93-25 −/− +miR93-expressing plasmid, 76.17±6.6%), indicating that miR93 (among the miR106b-93-25 cluster) is sufficient to promote perfusion recovery in experimental PAD. Our in vitro experiments showing antiangiogenic function of miR106b and no angiogenic effect of miR25 point out the significance of miR93 in regulating angiogenesis. In addition to increased angiogenesis after miR93 delivery, recovery was associated with increased arteriogenesis, decreased cell death, and significantly increased anti-inflammatory resident and infiltrating macrophages. Increased anti-inflammatory macrophages in miR93-treated ischemic leg correlated with increased angiogenesis and arteriogenesis and decreased cell death, which are well known to be downstream phenotype changes induced by M2-like macrophages. 8, 17, 19 These results suggest that miR93-mediated macrophage polarization plays a major role in regulating endothelial function to modulate vascular remodeling (including angiogenesis and arteriogenesis) and perfusion recovery.
Ischemia in the skeletal muscle induces a potent inflammatory response, resulting in the infiltration of immune cells, including monocytes/macrophages, that critically regulate the next stages of tissue recovery. 19, 20 Although several reports focused on the role of the monocytes that infiltrate the diseased tissue and differentiate to M1 or M2 phenotype to modulate tissue recovery, 15, [47] [48] [49] the status of the resident macrophages that can be considered the first immune cell population to respond to injury was overlooked in ischemic skeletal muscle. 19, 20 Because of their location in the ischemic skeletal muscle tissue, resident macrophages play critical roles in either aggravating or attenuating the extent of tissue damage, in addition to infiltrating monocyte/macrophages. Our data demonstrate that although under normal conditions miR93 deficiency does not affect the resident macrophage population, lack of miR93 in ischemic muscle dramatically decreased antiinflammatory tissue-resident macrophage population and tissue-infiltrating macrophages. These data suggest that miR93 modulates M2-like polarization of not only tissue-infiltrating but also tissue-resident macrophages.
RNA sequencing of WT and miR106b-93-25 −/− IGA identified potential miR93 targets that can regulate macrophage polarization. Although the top 3 genes induced in miR106b-93-25 −/− ischemic muscle (compared to WT), CXCL2, 50, 51 IRG1, 34, 52 and GM3893, were intimately associated with immune responses (except for GM3893, a long noncoding RNA), the top 3 downregulated genes, C1QTNF3, 53 MYH3, 54, 55 and ACTC1, 56, 57 were closely associated with skeletal muscle function. These data clearly indicated an inverse correlation between genes that regulate immune cell function and skeletal muscle perfusion recovery in miR106b-93-25 −/− ischemic muscle. Experiments conducted to understand miR93 regulation of skeletal muscle-macrophage interactions showed that miR93 induction in macrophages can have paracrine effects that decrease skeletal muscle injury/cell death. Furthermore, cytokine bead array showing that miR93 decreases tumor necrosis factor-α, IL-1β, and interferon-γ secretion (M1 cytokines well known to aggravate tissue injury) from ischemic macrophages suggests that increased M1 cytokine levels in miR106b-93-25 −/− ischemic muscle also contributed to aggravation of skeletal muscle injury. Further experiments are needed to fully dissect the role of miR93 in regulating paracrine effects of macrophages in experimental PAD.
Sequential analysis of top upregulated immune-related genes from RNA sequencing from miR106b-93-25 −/− versus WT mice showed that IRG1 can induce proinflammatory macrophage polarization and is modulated by miR93 in experimental PAD. IRG1 is highly expressed in macrophages during inflammation 58 and has been demonstrated to play important roles in regulating macrophage bactericidal activity by inducing the itaconic acid production. 52, 59 Macrophages treated with lipopolysaccharide were shown to have significantly higher (≈7-8 mmol/L) intracellular itaconic acid levels. 36 Itaconic acid (at 5 and 10 mmol/L, based on published report 36 ) showed a significant induction in iNOS expression but no changes in Arg1 expression, indicating that increased itaconic acid production in macrophages can induce M1-like macrophage polarization. Limited information is available on molecules that can regulate IRG1 expression. In this report, we show that although IRG1 is not a direct target of miR93, IRF9, which has the ability to induce IRG1, is a direct target of miR93, indicating that a complex miR93-IRF9-IRG1-itaconic acid pathway in macrophages regulates macrophage polarization and perfusion in experimental PAD.
Although our results do not exclude additional effects of macrophage polarization in modulating angiogenesis and arteriogenesis beyond immune cell function, we conclude that absolute, or relatively, less miR93 in hypoxia serum-starved macrophages results in increased IRF9-IRG1 expression, leading to increased itaconic acid production, which promotes proinflammatory M1-like polarization and contributes to impaired neovascularization (including angiogenesis and arteriogenesis) and decreased perfusion ( Figure 8G ) in experimental PAD.
